Two narcissus alkaloid compounds in narcissus roots as well as preparation method and application of two narcissus alkaloid compounds

Abstract

The invention discloses two narcissus alkaloid compounds in narcissus roots as well as a preparation method and application of the two narcissus alkaloid compounds. The invention provides two alkaloid compounds with novel structures, and activity research shows that the alkaloid compounds have anti-inflammatory activity, so that the alkaloid compounds have application prospects of being developed into anti-inflammatory drugs.

Description

Technical Field

[0001] The invention belongs to the field of natural drug chemistry and relates to the discovery, preparation and application of new natural products, and specifically to two narcissuscycline alkaloid compounds in narcissus roots, and a preparation method and application thereof. Background Art

[0002] Narcissus tazetta L.var.chinensis Roem. is the dried bulb of the Narcissus plant of the Amaryllis family. It is a perennial herb with an ovoid bulb and is mainly distributed in Jiangsu, Zhejiang, Fujian, Sichuan, Guizhou and other places in my country.

[0003] Pharmacopoeia records show that narcissus root has the effects of clearing away heat and detoxifying, dispersing nodules and reducing swelling. It can be used externally to treat sores and carbuncles, ulcers, mumps, parotitis and insect bites.

[0004] During the research on the chemical components of narcissus root, a new natural product was discovered, and the present invention is specially proposed. Summary of the invention

[0005] The first purpose of the present invention is to provide two narcissus cycline alkaloid compounds in the root of narcissus, the second purpose is to provide a preparation method of the narcissus cycline alkaloid compounds, and the third purpose is to provide the application of the narcissus cycline alkaloid compounds.

[0006] The above-mentioned purpose of the present invention is achieved through the following technical solutions:

[0007] An alkaloid compound having a structural formula as shown in Formula I or II, or a pharmaceutically acceptable salt or solvate thereof;

[0008]

[0009] A method for preparing the alkaloid compound represented by the above formula I comprises the steps of:

[0010] (1) extracting the root of narcissus root by heating with 95% by volume ethanol aqueous solution, filtering the extract, and concentrating until there is no alcohol taste to obtain an extract concentrate; loading the extract concentrate on a D-101 macroporous resin column, eluting with water, 30% by volume methanol aqueous solution, 60% by volume methanol aqueous solution, and pure methanol in sequence, combining the eluates of different solvents, and concentrating under reduced pressure to obtain extracts of different concentrations of eluted parts;

[0011] (2) taking the extract of the 60% methanol aqueous solution elution portion obtained in step (1), loading it onto a silica gel column, performing column chromatography separation, and then eluting it with a dichloromethane-methanol solvent gradient with a volume ratio of 100:1, 50:1, 25:1, 10:1, 5:1, 2:1, and 0:100 in sequence, and analyzing and combining them by thin layer chromatography to obtain 6 fractions A, B, C, D, E, and F;

[0012] (3) The fraction B obtained in step (2) was dissolved in methanol, separated by preparative liquid chromatography, and isocratically eluted with acetonitrile-water in a volume ratio of 25:75. The eluate at 19-20 min, the eluate at 25-26 min, and the eluate at 33-34 min were collected to obtain three sub-fractions 1, 2, and 3, which were concentrated and dried respectively. The chromatographic conditions of the preparative liquid chromatography were: YMC-Triart C 18 Chromatographic column, column size 250mm*10mm, particle size 5μm, eluent flow rate 4mL / min;

[0013] (4) Dissolve the sub-fraction 1 obtained in step (3) in methanol, separate by preparative liquid chromatography, use acetonitrile-water with a volume ratio of 6:94 as the mobile phase for elution, collect the eluate corresponding to the chromatographic peak with a retention time of 69 min, and concentrate and dry to obtain the eluate; the chromatographic conditions of the preparative liquid chromatography are: YMC-Triart C 18 Chromatographic column, column size 250mm*10mm, particle size 5μm, eluent 4mL / min.

[0014] Preferably, the solvent for heated extraction in step (1) is an ethanol aqueous solution with a volume fraction of 95%.

[0015] Preferably, in step (2), the silica gel column chromatography separation is carried out by dry loading: the extract is dissolved in methanol, the sample is dry mixed with silica gel, and the sample is loaded onto the silica gel column.

[0016] A method for preparing the alkaloid compound represented by the above formula II comprises the steps of:

[0017] (1) extracting the root of narcissus root by heating with 95% by volume ethanol aqueous solution, filtering the extract, and concentrating until there is no alcohol taste to obtain an extract concentrate; loading the extract concentrate on a D-101 macroporous resin column, eluting with water, 30% by volume methanol aqueous solution, 60% by volume methanol aqueous solution, and pure methanol in sequence, combining the eluates of different solvents, and concentrating under reduced pressure to obtain extracts of different concentrations of eluted parts;

[0018] (2) taking the extract of the 60% methanol aqueous solution elution portion obtained in step (1), loading it onto a silica gel column, performing column chromatography separation, and then eluting it with a dichloromethane-methanol solvent gradient with a volume ratio of 100:1, 50:1, 25:1, 10:1, 5:1, 2:1, and 0:100 in sequence, and analyzing and combining them by thin layer chromatography to obtain 6 fractions A, B, C, D, E, and F;

[0019] (3) The fraction B obtained in step (2) was dissolved in methanol, separated by preparative liquid chromatography, and isocratically eluted with acetonitrile-water in a volume ratio of 25:75. The eluate at 19-20 min, the eluate at 25-26 min, and the eluate at 33-34 min were collected to obtain three sub-fractions 1, 2, and 3, which were concentrated and dried respectively. The chromatographic conditions of the preparative liquid chromatography were: YMC-Triart C 18 Chromatographic column, column size 250mm*10mm, particle size 5μm, eluent flow rate 4mL / min;

[0020] (4) Dissolve the sub-fraction 2 obtained in step (3) in methanol, separate by preparative liquid chromatography, use acetonitrile-water with a volume ratio of 10:90 as the mobile phase for elution, collect the eluate corresponding to the chromatographic peak with a retention time of 55 min, and concentrate and dry to obtain the eluate; the chromatographic conditions of the preparative liquid chromatography are: YMC-Triart C 18 Chromatographic column, column size 250mm*10mm, particle size 5μm, flow rate 4mL / min.

[0021] Preferably, the solvent for heated extraction in step (1) is an ethanol aqueous solution with a volume fraction of 95%.

[0022] Preferably, in step (2), the silica gel column chromatography separation is carried out by dry loading: the extract is dissolved in methanol, the sample is dry mixed with silica gel, and the sample is loaded onto the silica gel column.

[0023] Use of the alkaloid compound represented by the above formula I or II or its pharmaceutically acceptable salt or solvate in the preparation of anti-inflammatory drugs.

[0024] Preferably, the anti-inflammatory drug uses the alkaloid compound represented by Formula I or II or a pharmaceutically acceptable salt or solvate thereof as an active ingredient, and is prepared into a pharmaceutically acceptable dosage form through a pharmaceutically acceptable carrier or excipient.

[0025] Preferably, the dosage forms include tablets, capsules, injections, aerosols, pills and pastes.

[0026] Beneficial effects:

[0027] The invention provides two alkaloid compounds with novel structures. Activity studies show that the alkaloid compounds have anti-inflammatory activity and thus have application prospects for being developed into anti-inflammatory drugs. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] Figure 1 The chemical structural formulas of compounds 1 and 2 prepared in Example 1;

[0029] Figure 2 , 3 is the mass spectrum of compounds 1 and 2;

[0030] Figure 4 , 5 For compounds 1 and 2 1 HNMR spectrum;

[0031] Figure 6 , 7 For compounds 1 and 2 13 C NMR spectrum;

[0032] Figure 8 , 9 HSQC spectra of compounds 1 and 2;

[0033] Fig.10 , 11 is the HMBC spectrum of compounds 1 and 2;

[0034] Fig.12 , 13 NOESY spectra of compounds 1 and 2;

[0035] Fig.14 , 15 For compounds 1 and 2 1 H- 1 H COSY spectrum. DETAILED DESCRIPTION

[0036] The essential contents of the present invention are described in detail below in conjunction with the embodiments, but the protection scope of the present invention is not limited thereto.

[0037] Example 1: Preparation and structural confirmation of new compounds

[0038] 1. Preparation method

[0039] This embodiment provides a method for preparing two narcissuscycline alkaloids from the root of narcissus, the steps are:

[0040] (1) 10 kg of narcissus root slices were taken, 10 times the volume of 95% ethanol aqueous solution was added at a ratio of 1 kg:10 L, and refluxed for extraction twice at 78° C., each extraction for 2 h, filtered after extraction, combined the extracts, and concentrated until there was no alcohol taste to obtain an extract concentrate; the extract concentrate was loaded on a D-101 macroporous resin column (inner diameter 20 cm×column bed height 100 cm), and eluted with 60 L of water, 60 L of 30% methanol aqueous solution, 60 L of 60% methanol aqueous solution, and 60 L of pure methanol in sequence, and the eluates from different solvents were combined respectively, and concentrated under reduced pressure at 60° C. to obtain extracts of different concentrations of eluted parts;

[0041] (2) Take the extract (29.42 g) of the 60% methanol aqueous solution elution part obtained in step (1), dissolve it with methanol, dry-mix it with silica gel (100-200 mesh, mass is twice the mass of the extract), load it onto a silica gel (100-200 mesh) column (inner diameter 8 cm×column bed height 80 cm), perform column chromatography separation, and then use dichloromethane-methanol solvent gradient elution with volume ratios of 100:1, 50:1, 25:1, 10:1, 5:1, 2:1, and 0:100 in sequence, eluting with 20 L of each solvent, and analyzing and combining it by thin layer chromatography (combining the eluates with the same thin layer chromatography development height) to obtain 6 fractions A, B, C, D, E, and F;

[0042] (3) The fraction B obtained in step (2) was dissolved in methanol, separated by preparative liquid chromatography, and isocratically eluted with acetonitrile-water in a volume ratio of 25:75 to obtain three sub-fractions 1 (19-20 min eluent), 2 (25-26 min eluent), and 3 (33-34 min eluent), which were concentrated and dried respectively; the chromatographic conditions of the preparative liquid chromatography were: YMC-Triart C 18 Chromatographic column, column size 250mm*10mm, particle size 5μm, eluent flow rate 4mL / min;

[0043] (4) The sub-fraction 1 obtained in step (3) was dissolved in methanol and separated by preparative liquid chromatography. The mobile phase was eluted with acetonitrile-water in a volume ratio of 6:94. The eluate corresponding to the chromatographic peak with a retention time of 69 min was collected and concentrated to obtain the target compound 1 (5.8 mg) with a purity of 99.5%. The chromatographic conditions of the preparative liquid chromatography were: YMC-Triart C 18 Chromatographic column, column size 250mm*10mm, particle size 5μm, eluent 4mL / min;

[0044] (5) The sub-fraction 2 obtained in step (3) was dissolved in methanol and separated by preparative liquid chromatography. The mobile phase was eluted with acetonitrile-water in a volume ratio of 10:90. The eluate corresponding to the chromatographic peak with a retention time of 55 min was collected and concentrated to obtain the target compound 2 (3.6 mg) with a purity of 99.5%. The chromatographic conditions of the preparative liquid chromatography were: YMC-Triart C 18 Chromatographic column, column size 250mm*10mm, particle size 5μm, flow rate 4mL / min.

[0045] 2. Structural Confirmation

[0046] Structural analysis of compounds: mainly using spectroscopy techniques, including mass spectrometry, nuclear magnetic resonance ( 1 H-NMR, 13 C-NMR, 2D-NMR) to identify its structure, the spectrum is as follows Figure 2 to Figure 15 As shown, the spectral data and analysis process are as follows.

[0047] 1. Structural analysis of target compound 1

[0048] Compound 1 is a brown amorphous powder, high resolution mass spectrum ESI-TOF-MS: 324.0714 [M+H] + The molecular formula of compound 1 is C 14 H 13 NO8, the exact molecular weight is 324.0714, and the degree of unsaturation is 9.

[0049] Compound 1 1 HNMR spectroscopy showed δ H There is an aromatic proton signal at 6.95 (1H, s, H-7), δ H There is a dioxymethylene proton signal at 6.08 (2H, d, J = 3.2 Hz), δ H 4.46 (1H, d, J=3.7Hz, H-1), δ H 4.40 (1H, d, J=4.8Hz, H-3), δ H 3.91-3.93 (1H, m, H-2), δ H There are four signals of secondary alcohol functional groups at 3.58-3.60 (1H, m, H-4). 13 C NMR spectrum showed 14 carbon signals, with a low field area of ​​δ C 166.0 (C-6) is the carbonyl carbon signal, and one methylene carbon (δ C 102.4), 5 methyl carbons (δ C 95.4, 72.8, 70.5, 70.3, 66.8), 7 quaternary carbon signals (δ C153.5, 143.8, 131.1, 112.9, 108.6 are carbon atoms on the A ring, δ C 135.3, 135.2 are olefinic carbons on the C ring). The HMBC spectrum shows that H-1 (δ H 4.46) and C-3(δ C 70.3),C-4a(δ C 135.3),C-10b(δ C 135.2),C-10a(δ C 112.9) and H-2(δ H 3.93) and C-3(δ C 70.3) / C-4(δ C 70.5) and C-4a (δ C 135.3) / C-10b(δ C 135.2) had no correlation, and the C-1(δ C 66.8) / C-2(δ C 72.8) and C-4a (δ C 135.3) / C-10b(δ C 135.2). From H-7 (δ H 6.95) and C-6(δ C 166.0),C-10a(δ C 112.9),C-9(δ C 153.5) and C-4a (δ C 135.3) / C-10b(δ C 135.2) had no correlation, confirming that C-7 (δ C 95.4) without hydroxyl substitution. 1 H- 1 H COSY spectrum of H-1(δ H 4.46) / H-2(δ H 3.93) and H-3(δ H 4.40) / H-4(δ H 3.59) confirmed that C-1(δ C 66.8)-C-2(δ C 72.8)-C-3(δ C 70.3)-C-4(δ C 70.5) fragment, H-1(δ H 4.46) / H-2(δ H 3.93) / H-4(δ H3.59) show a correlation, indicating that these protons are on the same side of the molecular plane. Based on the above data, the structure of compound 1 can be determined as Figure 1 As shown in Figure 1, the compound was named (1S,2S,3S,4S)-1,2,3,4,10-pentahydroxy-1,3,4-5-tetrahydro-[1,3]dioxo[4,5-j]phenanthrene-6(2H)-one.

[0050] 1 H NMR (600 MHz, DMSO): δ H 6.95(1H,s,H-7),δ H 6.08(2H,d,J=3.2Hz,OCH2O), δ H 4.46 (1H, d, J = 3.7 Hz, H-1), δ H 4.40 (1H, d, J = 4.8 Hz, H-3), δ H 3.91-3.93 (1H, m, H-2), δ H 3.58-3.60(1H,m,H-4). 13 C NMR (151 MHz, DMSO): δ C 166.0(C-6), 153.5(C-9), 143.8(C-10a), 135.3(C-4a), 135.2(C-10b), 131.2(C-10), 131.1(C- 8), 108.6(C-6a), 102.5(-OCH2O-), 95.3(C-7), 72.8(C-2), 70.5(C-4), 70.3(C-3), 66.8(C-1).

[0051] 2. Structural analysis of target compound 2

[0052] Compound 2 is a pale yellow amorphous powder, high resolution mass spectrum ESI-TOF-MS: 308.0768 [M+H] + The molecular formula of compound 2 is C 14 H 13 NO7, the exact molecular weight is 308.0768, and the degree of unsaturation is 9.

[0053] Compound 2 1 H-NMR, 13 The C-NMR spectrum is very similar to that of compound 1, indicating that it has the same skeleton as compound 1. The difference is that 1 H-NMR spectrum shows an additional aromatic proton δ in the aromatic ring region H 7.24 (H-10), and finally the HMBC spectrum showed that H-1 (δ H4.73) and C-3(δ C 67.8), C-4a(δ C 136.2), C-10b(δ C 110.0), C-10a(δ C 134.9) and H-2(δ H 3.78) and C-3(δ C 67.8) / C-4(δ C 67.9) and C-4a (δ C 136.2) / C-10b(δ C 110.0) has no correlation, H-7(δ H 7.49) and C-6 (δ C 162.0), C-10a(δ C 134.9), C-9(δ C 152.6); H-10(δ H 7.24)C-7(δ C 104.6), C-10b(δ C 110.0), C-8(δ C 147.7) and the related structure of compound 2 were further verified (e.g. Figure 1 2), and the compound was named (1S,2S,3S,4S)-1,2,3,4-tetrahydroxy-1,3,4-tetrahydro-[1,3]dioxo[4,5-j]phenanthrene-6(2H)-one.

[0054] 1 H NMR (600 MHz, DMSO): δ H 7.49(1H,s,H-7),δ H 7.24(1H,s,H-10),δ H 6.14(2H,s,OCH2O),δ H 4.73(1H,s,H-1),δ H 4.42(1H,s,H-3),δ H 3.78 (1H, d, J = 2.1 Hz, H-2), δ H 3.78 (1H, d, J = 2.1 Hz, H-4). 13 C NMR (151 MHz, DMSO): δ C162.0(C-6), 152.6(C-9), 134.9(C-10a), 136.9(C-4a), 110.0(C-10b), 103.5(C-10), 147.7(C- 8), 122.2(C-6a), 102.3(-OCH2O-), 104.6(C-7), 68.3(C-2), 67.9(C-4), 67.8(C-3), 65.8(C-1).

[0055] Example 2: Activity of new compounds

[0056] 1. Experimental Materials and Instruments

[0057] Compounds 1 and 2 prepared in Example 1; mouse mononuclear macrophage RAW264.7 (Shanghai Cell Bank, Chinese Academy of Sciences), DMEM complete medium (Beijing Solebold Technology Co., Ltd.), fetal bovine serum (FBS) (Beijing Solebold Technology Co., Ltd.), lipopolysaccharide (LPS) (Beijing Solebold Technology Co., Ltd.), DMSO (Shanghai Yishen Biotechnology Co., Ltd.), NO detection kit (Shanghai Biyuntian Biotechnology Co., Ltd.), phosphate buffered saline PBS (Beijing Solebold Technology Co., Ltd.), microplate reader (Molecular Devices: SpectraMax i3, USA), MCO-20ACI CO2 constant temperature incubator (Thermo Corporation, USA), BS125S one-tenth of a balance (Mettler-Toledo, Switzerland).

[0058] 2. Experimental Methods

[0059] The anti-inflammatory activity of compounds 1 and 2 was evaluated by NO inhibition rate in the commonly used RAW264.7 cells. The specific evaluation method is as follows:

[0060] The compound was dissolved in dimethyl sulfoxide (DMSO) to a 100 mM stock solution and stored in a -20°C refrigerator. When used, it was adjusted to an appropriate concentration using DMEM medium containing 1% fetal bovine serum (FBS). In a clean bench, 5 mg of lipopolysaccharide was dissolved in 5 mL of PBS and dispensed into sterile centrifuge tubes. Each tube of 1 mL was sealed with a sealing film and stored in a -20°C refrigerator.

[0061] RAW264.7 cells in the logarithmic growth phase were taken at a density of 2×10 5Cells were inoculated at a density of 10 cells / well in a 24-well plate and cultured for 24 hours. The blank group and the model group were replaced with 500 μL DMEM complete medium per well, and the drug-treated group was replaced with 500 μL DMEM complete medium containing different concentrations (6.25 μM, 12.5 μM, 25 μM, 50 μM, 100 μM) of the compound per well. After 2 hours, 0.5 μL of LPS solution was added to each well except the blank group. After 24 hours of continuous culture, 50 μL of cell supernatant was collected from each well and the wells were repeated 3 times. The absorbance of each well at 540 nm was detected by an enzyme reader. According to the formula [(A 模型 -A 给药 ) / (A 模型 -A 空白 )]×100% to calculate the inhibition rate of cellular NO release.

[0062] 3. Experimental Results

[0063] The measurement results are shown in Tables 1 and 2.

[0064] Table 1 Inhibitory effect of different concentrations of compound 1 on LPS-induced NO production in RAW264.7 cells

[0065]

[0066] Table 2 Inhibitory effect of different concentrations of compound 2 on LPS-induced NO production in RAW264.7 cells

[0067]

[0068] The test results show that the compounds 1 and 2 provided in the examples have obvious anti-inflammatory effects and show a certain dose dependence. Therefore, compounds 1 and 2 have the prospect of being developed into anti-inflammatory drugs.

[0069] The purpose of the above-mentioned embodiments is to specifically introduce the essential content of the present invention, but those skilled in the art should know that the protection scope of the present invention should not be limited to the specific embodiments.

Claims

1. An alkaloid compound having a structural formula as shown in Formula I or II, or a pharmaceutically acceptable salt or solvate thereof; 2. A method for preparing the alkaloid compound represented by formula I in claim 1, characterized in that: Includes steps: (1) extracting the root of narcissus root by heating with 95% by volume ethanol aqueous solution, filtering the extract, and concentrating until there is no alcohol taste to obtain an extract concentrate; loading the extract concentrate on a D-101 macroporous resin column, eluting with water, 30% by volume methanol aqueous solution, 60% by volume methanol aqueous solution, and pure methanol in sequence, combining the eluates of different solvents, and concentrating under reduced pressure to obtain extracts of different concentrations of eluted parts; (2) taking the extract of the 60% methanol aqueous solution elution portion obtained in step (1), loading it onto a silica gel column, performing column chromatography separation, and then eluting it with a dichloromethane-methanol solvent gradient with a volume ratio of 100:1, 50:1, 25:1, 10:1, 5:1, 2:1, and 0:100 in sequence, and analyzing and combining them by thin layer chromatography to obtain 6 fractions A, B, C, D, E, and F; (3) The fraction B obtained in step (2) was dissolved in methanol, separated by preparative liquid chromatography, and isocratically eluted with acetonitrile-water in a volume ratio of 25:

75. The eluate at 19-20 min, the eluate at 25-26 min, and the eluate at 33-34 min were collected to obtain three sub-fractions 1, 2, and 3, which were concentrated and dried respectively. The chromatographic conditions of the preparative liquid chromatography were: YMC-Triart C 18 Chromatographic column, column size 250mm*10mm, particle size 5μm, eluent flow rate 4mL / min; (4) Dissolve the sub-fraction 1 obtained in step (3) in methanol, separate by preparative liquid chromatography, use acetonitrile-water with a volume ratio of 6:94 as the mobile phase for elution, collect the eluate corresponding to the chromatographic peak with a retention time of 69 min, and concentrate and dry to obtain the eluate; the chromatographic conditions of the preparative liquid chromatography are: YMC-Triart C 18 Chromatographic column, column size 250mm*10mm, particle size 5μm, eluent 4mL / min.

3. The preparation method according to claim 2, characterized in that: The solvent for heating and extraction in step (1) is an ethanol aqueous solution with a volume fraction of 95%.

4. The preparation method according to claim 2, characterized in that: In step (2), dry loading is adopted for silica gel column chromatography separation: the extract is dissolved in methanol, the sample is dry mixed with silica gel, and the sample is loaded onto the silica gel column.

5. A method for preparing the alkaloid compound represented by formula II in claim 1, characterized in that: Includes steps: (1) extracting the root of narcissus root by heating with 95% by volume ethanol aqueous solution, filtering the extract, and concentrating until there is no alcohol taste to obtain an extract concentrate; loading the extract concentrate on a D-101 macroporous resin column, eluting with water, 30% by volume methanol aqueous solution, 60% by volume methanol aqueous solution, and pure methanol in sequence, combining the eluates of different solvents, and concentrating under reduced pressure to obtain extracts of different concentrations of eluted parts; (2) taking the extract of the 60% methanol aqueous solution elution portion obtained in step (1), loading it onto a silica gel column, performing column chromatography separation, and then eluting it with a dichloromethane-methanol solvent gradient with a volume ratio of 100:1, 50:1, 25:1, 10:1, 5:1, 2:1, and 0:100 in sequence, and analyzing and combining them by thin layer chromatography to obtain 6 fractions A, B, C, D, E, and F; (3) The fraction B obtained in step (2) was dissolved in methanol, separated by preparative liquid chromatography, and isocratically eluted with acetonitrile-water in a volume ratio of 25:

75. The eluate at 19-20 min, the eluate at 25-26 min, and the eluate at 33-34 min were collected to obtain three sub-fractions 1, 2, and 3, which were concentrated and dried respectively. The chromatographic conditions of the preparative liquid chromatography were: YMC-Triart C 18 Chromatographic column, column size 250mm*10mm, particle size 5μm, eluent flow rate 4mL / min; (4) Dissolve the sub-fraction 2 obtained in step (3) in methanol, separate by preparative liquid chromatography, use acetonitrile-water with a volume ratio of 10:90 as the mobile phase for elution, collect the eluate corresponding to the chromatographic peak with a retention time of 55 min, and concentrate and dry to obtain the eluate; the chromatographic conditions of the preparative liquid chromatography are: YMC-Triart C 18 Chromatographic column, column size 250mm*10mm, particle size 5μm, flow rate 4mL / min.

6. The preparation method according to claim 5, characterized in that: The solvent for heating and extraction in step (1) is an ethanol aqueous solution with a volume fraction of 95%.

7. The preparation method according to claim 5, characterized in that: In step (2), dry loading is adopted for silica gel column chromatography separation: the extract is dissolved in methanol, the sample is dry mixed with silica gel, and the sample is loaded onto the silica gel column.

8. Use of the alkaloid compound represented by formula I or II as claimed in claim 1 or its pharmaceutically acceptable salt or solvate in the preparation of anti-inflammatory drugs.

9. The use according to claim 8, characterized in that: The anti-inflammatory drug uses the alkaloid compound represented by formula I or II or its pharmaceutically acceptable salt or solvate as an active ingredient, and is prepared into a pharmaceutically acceptable dosage form through a pharmaceutically acceptable carrier or excipient.

10. The use according to claim 9, characterized in that: The dosage forms include tablets, capsules, injections, aerosols, pills and ointments.

Images